What has been the landscape for venture capital investment in early-stage biotech in 2022 and what to expect in the coming years? Who are the current investors in Seed and Series A biotech: pure players, newcomers? Which funds are the most developed in venture capital? What can we observe in terms of investment geography? Are there significant trends in terms of size of funds and capacity of investment? What are the preferred tools and networks for investment?